Identification of Gene Defects Helps Prostate Cancer Treatment

The disease's underlying mechanisms vary significantly from one individual to the next and therefore, prostate cancer treatments should be designed individually for each patient according to their personal clinical picture.

Several new treatments have been developed for prostate cancer in the past ten years. The same problem remains: the inability to predict which treatment will be most effective for each patient. It has been known for some time that prostate cancer growth is stimulated by male hormones called androgens. Hormonal therapy, which prevents the production or effects of androgens, has been the so-called gold standard in treating the advanced form of the disease.

However, prostate cancer can reactivate the androgen receptor-signaling pathway during treatment. Some types of prostate cancer eventually become independent of androgens. The scientists have found a new mechanism related to the activation of the transcription cofactor Hairy and Enhancer of Split 6 (HES6) as the result of gene fusion, which leads to this type of cancer cell development. These types of prostate cancer need non-hormonal therapy.

Tapio Visakorpi, MD, PhD, a professor and lead investigator of the study, said, “Recent genome studies have shown that even though prostate cancer initiates in a single cell of origin, several cancer cell subpopulations with different genome types emerge as the disease progresses. This is not a single disease; several mechanisms lead to the emergence of the disease. Therefore, it's important to identify those genome defects in each patient that occur in all cancer cells, that is, the so-called truncal mutations, and target the treatment to them. This requires taking multiple samples from the patient. The processing of samples also needs to be improved to make them more suitable for molecular analysis than the current methods. We've developed a new processing method for cancerous tissue.”

Related Links:
University of Tampere